AbbVie
US immunology powerhouse — Humira (world's top-selling biologic 2012–2023) and Skyrizi/Rinvoq driving next-generation antibody manufacturing scale-up.
- Country
- United States
- Revenue
- $56.3B
- Employees
- ~50,000 emp
FDA GMP
GMP EU
Coverage
| CN | EU | US | |
|---|---|---|---|
| specialty-fine-chem | ✓ | ✓ | ✓ |
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Biologics | therapeutics-platforms | Low | → |
| Biosynthetic hyaluronic acid | specialty-fine-chem | Low | → |
| Bispecific & multispecific antibodies | therapeutics-platforms | Low | → |
| Recombinant botulinum toxin (biosynthetic Botox) | specialty-fine-chem | Low | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.